Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Padsevonil adjunctive therapy for drug-resistant focal-onset seizures
NL-OMON49060Phase 3Withdrawn
- Sponsor
- UCB
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of padsevonil in epilepsy and Focal Onset Epilepsy (4 arms), sponsored by UCB. Planned start Jan 2019; status: withdrawn.
02
Drugs
padsevonil
03
Conditions
epilepsyFocal Onset Epilepsy
Beyond the preview
Go deeper on NL-OMON49060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49060.